Merck Can't Get Fed. Circ. To Reconsider Axing MS Drug Patents
The Federal Circuit on Thursday refused to reconsider decisions invalidating Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, turning aside the German drugmaker's claim that the court set an...To view the full article, register now.
Already a subscriber? Click here to view full article